Skip to content

Transvaginal Tape (TVT) Secur Versus TVT Randomised Controlled Trial (RCT)

Tension-free Vaginal Tape Management of Stress Incontinence in Women: Randomized Trial of TVT Secur Versus TVT

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00685217
Enrollment
74
Registered
2008-05-28
Start date
2008-05-31
Completion date
2012-04-30
Last updated
2016-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Incontinence, Stress

Brief summary

This randomized multi-centre trial will recruit women with stress urinary incontinence who need surgical treatment for their condition. 300 women will be allocated either to receive a TVT Secur or a standard TVT surgical procedure. The main outcome is effectiveness of the procedure, determined using a 1-hour pad test (which tests for urine leakage) 12 months after surgery. The study will be carried out in 4 to 6 centers and will involve urogynaecologists, urologists and general obstetrician-gynaecologists: all clinicians will have received adequate training.

Interventions

PROCEDURETVT Secur (Gynecare)

Sling device for stress urinary incontinence

PROCEDURETVT (Gynecare)

Sling procedure for stress urinary incontinence

Sponsors

University of Alberta
CollaboratorOTHER
Johnson & Johnson Medical Companies
CollaboratorINDUSTRY
University of Calgary
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Women with stress incontinence, defined as leaking with increased abdominal pressure * Eligible for both types of surgery

Exclusion criteria

Women who: * Have vaginal prolapse requiring surgical repair * Have had previous incontinence surgery * Have overactive bladder or incontinence is caused only by bladder overflow * Intend to have further children * Have Alzheimer's or Parkinson's disease, progressive neurological disease such as multiple sclerosis, or are immunocompromised * Are unable to understand English * Will be unavailable for follow-up

Design outcomes

Primary

MeasureTime frame
Standardised pad test: cure is defined as less than 1g gain in pad weight over the duration of the test12 months following surgery

Secondary

MeasureTime frameDescription
Incontinence-related quality of life (UDI-6, IIQ-7)6 weeks and 12 months following surgery
Sexual function (PISQ-12)12 months following surgery
Satisfaction with surgical outcome12 months following surgeryPatients will be asked about the expectations they had before surgery, and asked if the outcome had met expectations. Women will be asked about satisfaction with the surgical outcome, if they would have the same operation again under the same circumstances, and if they would recommend the same operation to someone else with the same problem.
Return to usual activitiesup to 12 months following surgery
Subjective evidence of cure12 months following surgery
Surgical complicationsup to 12 months following surgery
Costup to 12 momths following surgery
Utility (15-D)6 weeks and 12 months following surgery
Voiding dysfunction12 months following surgery

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026